<DOC>
	<DOCNO>NCT00136448</DOCNO>
	<brief_summary>This study add interleukin-2 ( IL-2 ) regimen post-remission therapy consist high-dose ara-C . Patients AML first remission receive 3 cycle high-dose ara-C follow continuous infusion bolus interleukin-2 ( IL-2 ) . We , researcher Dana-Farber Cancer Institute , plan evaluate immunologic effect treatment patient .</brief_summary>
	<brief_title>High Dose Ara-C ( HDAC ) Interleukin-2 ( IL-2 ) Patients With Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>Patients receive standard remission induction therapy daunorubicin dose 45 mg/m2/day 3 day continuous infusion cytarabine dose 200 mg/m2/day 7 day . Those patient enter remission status preserve liver kidney function receive 3 cycle post-remission therapy consist high-dose cytarabine dose 3000 mg/m2 every 12 ( q12 ) hour day 1 , 3 5 ( total 6 dos ) . Patients still remission receive interleukin-2 ( IL-2 ) upon count recovery dose 8.1 X 10^5 U/m2/day continuous infusion 10 week . In addition , patient receive bolus IL-2 dose 6 X 10^5 U/m2 intravenous bolus weekly 6 dos day 63 . Patients see weekly basis treatment examination bloodwork . At end treatment , patient physical exam bloodwork perform monthly two year , 4 time per year two year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients must AML base FrenchAmericanBritish ( FAB ) criterion . Patients must total bilirubin &lt; 2.0 mg/dL , SGOT &lt; 90 IU/mL , alkaline phosphatase &lt; 250 U/mL serum creatinine &lt; 2.0 mg/dL . Age 18 year great . History antecedent hematologic malignancy myelodysplastic syndrome ( MDS ) . Uncontrolled infection . History previous concomitant malignancy nonmelanoma skin cancer . Evidence central nervous system ( CNS ) leukemia . Current use corticosteroid . Prior treatment AML , hydroxyurea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>AML</keyword>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>cytarabine</keyword>
	<keyword>interleukin-2</keyword>
</DOC>